


Corona-Swiss Ltd Accelerates Cancer Detection Test w/ Blockchain Along w/ Ryukyu Univ & Local Gov't

Corona-Swiss will conduct Cancer Test proof experiment to 1,500 people in le Village Okinawa. Featuring its 10 minutes result evaluation with 99% accuracy rate

SLIEMA, MALTA, December 21, 2018 /EINPresswire.com/ -- Corona-Swiss Ltd., who is the owner of BIOHAL Network announced today that they will carry out a proof experiment by performing cancer risk screening for 1,500 le-islanders in Okinawa Prefecture. This cancer early detection test will start in June of 2019 and it will



Early Cancer Detection Technique in approximately 10 minutes with 99% accuracy rate. Aiming to eliminate death caused by cancer in the future.

run for three years. This is with the cooperation of the University of Ryukyu, and the Local Government of Ie-Village. The official agreement was made on the 1st of November and the announcement was released last 30th of November.



The life of the individuals and their families can live with a peace of mind knowing there is an accurate early detection test with preventive medicine from BIOHAL."

Yuki Hasegawa

Corona-Swiss, Ltd., aims to bridge the gap by giving the people access to its innovative solution and blockchain technique to store cancer data accurately as the medical cost for treatment has gone up, and not everyone can afford to foot the medical bills.

"The life of the individuals and their families can live with a peace of mind knowing there is an accurate early detection test with preventive medicine from BIOHAL." Says Yuki Hasegawa, Founder/CEO, BIOHAL.

PROTEO®, a cancer risk screening test which is an epoch-

making technique, that can evaluate the presence of any cancer in just 10 minutes. The procedure of PROTEO will continue until the risk test result of cancer goes out from a drop of blood. In comparison with other liquid biopsy tests, PROTEO features its 99% cancer accuracy test result rate. Also, the <u>proteo liquid biopsy test</u> can carry out to a pregnant woman and child safe because radiation is not used in this test.

Corona-Swiss Ltd., utilizes the data collected through PROTEO by using a blockchain (distributed ledger technology) technique and manages it. The Blockchain architecture is matched with a concept of patients' data management of Corona-Swiss, and each patient can review the result of their screening test without any problem as well as check other DNA data as it is secured and made personal. The company will save know-how technique of the data technology for the next generation.

Corona-Swiss, Ltd

. email us here

This press release can be viewed online at: http://www.einpresswire.com

Disclaimer: If you have any questions regarding information in this press release please contact the company listed in the press release. Please do not contact EIN Presswire. We will be unable to assist you with your inquiry. EIN Presswire disclaims any content contained in these releases. © 1995-2018 IPD Group, Inc. All Right Reserved.